Testicular Cancer: Biology to Bedside.

Abstract

Testicular cancer is the first solid tumor with a remarkably high cure rate. This success was only made possible through collaborative efforts of basic and clinical research. Most patients with distant metastases can be cured. However, the majority of these patients are diagnosed at a young age, leaving many decades for the development of treatment-related complications. This has magnified the importance of research into survivorship issues after exposure to platinum-based chemotherapy. This research, along with research into newer biomarkers that will aid in the diagnosis and surveillance of patients and survivors of testicular cancer, will continue to advance the field and provide new opportunities for these patients. There also remains the need for further therapeutic options for patients who unfortunately do not respond to standard treatment regimens and ultimately die from this disease, including a cohort of patients with late relapses and platinum-refractory disease. Here we discuss the advancements in management that led to a highly curable malignancy, while highlighting difficult situations still left to solve as well as emerging research into novel biomarkers.

• Authors: Jennifer King, Nabil Adra, Lawrence H Einhorn
• Journal: Cancer research (Cancer Res) Vol. 81 Issue 21 Pg. 5369-5376 (11 01 2021) ISSN: 1538-7445 [Electronic] United States
• PMID: 34380632 (Publication Type: Journal Article, Review)
• Copyright: ©2021 American Association for Cancer Research.

Chemical References

• Antineoplastic Agents
• Biomarkers, Tumor

Topics

• Antineoplastic Agents (therapeutic use)
• Biomarkers, Tumor (metabolism)
• Humans
• Male
• Quality of Life
• Risk Factors
• Testicular Neoplasms (diagnosis, drug therapy, metabolism)